The relationship between prostate cancer and apoptosis

Abstract

Prostate is the largest accessory gland of male genital tract and the beginning part of male urethra. Prostate cancer is the most common internal malignancy in males. Prostate cancer is ranked as second in death from to cancer. A malignant disease is known as uncontrolled proliferation of cells. Beside excessive proliferation, decreased apoptosis was also observed contribute to the development of malignancy. Apoptosis (programmed cell death) plays an important role in many diseases and free radical damage, triggers by cytokines and inflammatory injury. This review has been prepared to show the interesting link between apoptosis and cancer and to provide collective source to who want to do research on this subject.

Keywords

• Prostate, cancer, apoptosis.

Prostat kanseri ve apoptozis ilişkisi

Abstract

Prostat erkek genital sisteminin en büyük aksesuar bezi olup, erkek üretrasının başlangıç kısmını oluşturur. Prostat karsinomu erkek cinste en çok görülen internal malignitedir. Kansere bağlı ölümlerde ise ikinci sırada yer alır. Malign hastalıklar, klasik olarak kontrolsüz aşırı hücre proliferasyonunun olduğu hastalıklar olarak bilinir. Oysa aşırı proliferasyonun yanında azalmış apoptozisin de malignite gelişimine katkıda bulunduğu görülmüştür. Apoptozis (programlanmış hücre ölümü) birçok hastalıkta önemli rol oynar ve serbest radikal hasarı, sitokinler ve inflamatuar yaralanma tarafından tetiklenir. Bu derleme; apoptozis ve kanser arasındaki ilgi çekici bağlantıları göstermek ve bu konuda araştırma yapmak isteyenlere toplu bir kaynak sunmak amacıyla yapıldı.

Keywords

• Prostat, kanser, apoptozis.

References

1. Arıncı K. Uygulamalı Anatomi, Türkiye Klinikleri Yayıne- vi, Ankara 1993.
2. Erkoçak A.: Özel Histoloji, 4. Baskı, Ankara Tıp Yayını, Ankara 1982.
3. Tortora GJ. Principles of human Anatomy, 4. ed. Harper and Row Publishers, New York 1986.
4. Arıncı K. Anatomi, 4. Baskı, Güneş Kitabevi, Ankara 2006.
5. Elhan, A. İnsan Anatomi Atlası (çeviri: Köpf-Maier, P Wolf-Heidegger’s Atlas of Human Anatomy. 5. ed., Gü- neş Kitabevi, Ankara 2001.
6. Elhan, A. Temel Klinik Anatomi (çeviri. Moore KL.), İkinci baskı, Güneş Kitabevi, 2006.
7. Gökmen FG. Sistematik Anatomi, Güven Yayınevi, İzmir 2003.
8. Şakul BU. TUS için Anatomi, Ankara Üniversitesi Basıme- vi, Ankara 2001.

9. Drake RI, Vogl W, Mitchell AWM. Gray’s Anatomy for student, Churchill Livingstone, 2005.
10. Standring S. Gray’s Anatomy. The Anatomical Basis of Clinical Practise, 38. ed., Churchill Livingstone, New York 2005.
11. Wilt TJ, Brawer MK, Barry MJ, Jones KM, et al. The Prostate cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): Design and baseline results of a randomized controlled trial comparing radical prostatectomy to watch- ful waiting for men with clinically localized prostate can- cer. Contemp Clin Trial 2009;30:81–87.
12. Chu TM, Kawinski E, Hibi N, et al. Prostate specific anti- gen domain of human prostate specific antigen identified with monoclonal antibodies. J Urol 1989;141:152-158.
13. Lilja II: A kallikrein like serin protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 1985;76:1889-1892.
14. Christensson A, Björk T, Nilsson O, et al: Serum prostate specific antigen complexed to 1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993;150:100-105.
15. Mc Cormack RT, Rittenhause HG, Finlay JA, et al: Mo- lecular form of prostate specific antigen and the human kallikrein gene family: a new era. Urology 1995;45:729- 744.
16. Youlanda T Logan, Pharm D, Myra T. Belgeri, Pharm D, CGR BCPS 2 Monotherapy versus combination drug ther- apy for the treatment of benign prostatic hyperplasia, Am J Geriatr Pharmacother 2005;3:103-114.
17. Mark J. Speakman. Lower urinary tract symptoms sugges- tive of benign prostatic hyperplasia (LUTS/BPH): More than treating symptoms? Eur Urology 2008;7:680–689.
18. Mete Ç. Kronik prostatit/Kronik pelvik ağrı sendromu, Türk Üroloji Dergisi 2005;31:569-573.
19. Akdaş A, Çevik İ. BPH-Benign Prostat Hiperplazisi. He- kimler Yayın Birliği, Ankara 1996.
20. Canatan H, Halifeoğlu İ, Gürsu MF, Ardıçoğlu A, et al. Serum leptin düzeylerinin prostat kanserli ve benign prostat hiperplazili hastalarda ve sağlıklı kontrollerde (genç ve yaşlı) saptanması. Fırat Tıp Dergisi 2004;9:112
21. Gleason DF. Histologic gradeing of prostate cancer. A perspective. Hum Pathol 1992;23;273-279.
22. Hwang C, Heath EI. Angiogenesis inhibitors in the treat- ment of prostate cancer, J Hematol Oncol 2010;3:26-30.
23. Noonan EJ, Place RF, Basak S, Pookot D, Li LC. MiR- 449a causes Rb-dependent cell cycle arrest and senescence in prostate cancer cells. Oncotarget 2010;1:349–358.
24. Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev 2010;24:1967-2000.
25. Choi KC, Park SY, Lim BJ, Sung AR, Lee YH. Procya- nidin B3, an inhibitor of histone acetyltransferase, en- hances the action of antagonist for prostate cancer cells via inhibition of p300-dependent acetylation of androgen re- ceptor Running title: Procyanidin B3 is a histone acetyl- transferase inhibitor. Biochem J 2010;3:23-29.
26. Luo B, Wang AL. An update of the markers for prostate cancer. Zhonghua Nan Ke Xue 2010;16:531-535.
27. Hail N, Chen P, Bushman LR. Teriflunomide (le- flunomide) promotes cytostatic, antioxidant, and apoptotic effects in transformed prostate epithelial cells: Evidence supporting a role for teriflunomide in prostate cancer che- moprevention. Neoplasia 2010;12:464–475.
28. da Motta VP, Malafaia O, Ribas-Filho JM, et al. CAS- PASE-3 and CD-34 expression in prostate adenocarci- noma. Rev Col Bras Cir 2009;36:223-229.
29. Warner TF. Apoptosis. Lancet 1972;2:1252-258.
30. Yan L, John M, Qiaohong L. Chemoprotective effects of curcuma aromatica on esophageal carcinogenesis. Ann Surg Oncol 2008;515-523.
31. Ulukaya E. Apoptozis Ders Notları Ankara, 2003
32. Wei Q, Kazimierz S, Kadiiska M. Mechanism of arsenic- induced cross tolerance to nickel cytotoxicity, genotoxicit and apoptosis in rat liver epithelial cells. Toxicological Science 2001;63:189-195.
33. Kiess W, Gallaher B. Hormonal control of programmed cell death/apoptosis. European Journal of Endocrinology 1998;138;482–491.
34. Sanmartín C, Plano D, Palop JA. Selenium compounds and apoptotic modulation: a new perspective in cancer therapy. Mini Rev Med Chem 2008;8:1020-1031.
35. Choen GM. Caspases, the executioners of apoptozis. Bio- chem J 1997;326:1-16.
36. Lee D, Scott AL, Jerry AL. Potent and selective nonpep- tide inhibitors of caspases 3 and 7 inhibit apoptozis and maintain cell functionally. J Biol Chem 2000;275:16007- 16014.
37. Ozawa H, Keone RW, Marcilla AE. Thetapeutic stragies targetting caspase inhibition following spinal cord injury in rats. Exp Neurol 2002;177:306-313.
38. Wang KK. Calpain and caspase can you tell the differ- ance? Trends Neuroscience 2000;23:20-26.
39. Keane RW, Kraydieh S, Lotock G. Apoptotic and anti- apoptotic mechanisms following spinal cord injury. J Neu- ropathol Exp Neurol 2001;60:422-429.
40. Li M, Ona Vo, Chen M. Functional role and theropetic implications of neuronal caspase 1 and 3 in a mause model of 2000;99:333-342. injury. Neuroscience
41. Mukae N, Enari M, Sakahiro H, et al. Molecular cloning and charecterization of human caspase activated DNase. Proc Natl Acad 1998;95:9123-9128.
42. Nuttal ME, Nadeau DP, Fisher PW, et al. Inhibition of caspase 3 like activity prevents apoptozis while retaining functionally of human condrycytes in-vitro. J Bone Joint Surg 2000;18:356-363.
43. Kidd VJ, Lahti JM, Teitz T. Proteolytic regulation of apoptosis. Semin Cell Dev Biol 2000;11:191-201.
44. Norberg E, Orrenius S, Zhivotovsky B. Mitochondrial regulation of cell death: processing of apoptosis-inducing factor 2010;396:95-100. Biophys Res Commun
45. Zhang Z, Kreps CJ, Guth L. Experimental analysis of pro- gressive necrosis after spinal cord trauma in the etiological role of the inflammatory responce. Exp Neurol 1997;143:141-152.
46. Chu TM, Kawinski E, Hibi N, et al. Prostate specific anti- gen domain of human prostate specific antigen identified with monoclonal antibodies. J Urol 1989;141:152-156.
47. Ricci JE, Gottlieb RA, Gren DR. Caspase-mediated loss of mitochondrial function and generation of reactive oxygen species during apoptosis. J Cell Biology 2003;160;65-75.
48. Kalra N, Prasad S, Shukla Y. Antioxidant potential of black tea against 7,12-dimethylbenz(a)anthracene-induced oxidative stress in Swiss albino mice. J Environ Pathol Toxicol Oncol 2005;24:105-114.
49. Coussens LM, Werb Z. Inflamattion and cancer. Nature 2002;420:860-867.
50. Taija M, Kiviharju-af H, Marikki L. Genetic changes and DNA damage responses in the prostate. Prostate 2008;68:902-918.
51. De Marzo AM, Nakai Y, Nelson WG. Inflamation, atro- phy and prostate carcinogenesis. Urol Oncol 2007;25:398
52. Lu J, ashwell K, Ken WS, Waite P. Advances in spinal cord injury: Role of apoptosis. Spine 2000;25:1859-1866.
53. Helts SW. To die or not to die: An overwievof apoptozis and its role in disease. JAMA 1998;278:300-307.
54. Kiess W, Gallaher B. Hormonal control of programmed cell death apoptosis. Eur J Endocrin 1998;18:482-491.